A double-blind, placebo-controlled crossover study to assess the pharmacokinetic profile and the physiological and behavioral effects of repeat rivastigmine (Exelon) administration in young healthy male volunteers

Trial Profile

A double-blind, placebo-controlled crossover study to assess the pharmacokinetic profile and the physiological and behavioral effects of repeat rivastigmine (Exelon) administration in young healthy male volunteers

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2014

At a glance

  • Drugs Rivastigmine (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics
  • Acronyms RIVA-1
  • Most Recent Events

    • 22 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top